0000950170-24-005888.txt : 20240119 0000950170-24-005888.hdr.sgml : 20240119 20240119183006 ACCESSION NUMBER: 0000950170-24-005888 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240119 FILED AS OF DATE: 20240119 DATE AS OF CHANGE: 20240119 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Binder Gwendolyn CENTRAL INDEX KEY: 0001791742 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39103 FILM NUMBER: 24546675 MAIL ADDRESS: STREET 1: C/O CABALETTA BIO, INC. STREET 2: 2929 ARCH STREET, SUITE 600 CITY: PHILADELPHIA STATE: PA ZIP: 19104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cabaletta Bio, Inc. CENTRAL INDEX KEY: 0001759138 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2929 ARCH STREET STREET 2: SUITE 600 CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: (267) 759-3100 MAIL ADDRESS: STREET 1: 2929 ARCH STREET STREET 2: SUITE 600 CITY: PHILADELPHIA STATE: PA ZIP: 19104 4 1 ownership.xml 4 X0508 4 2024-01-19 0001759138 Cabaletta Bio, Inc. CABA 0001791742 Binder Gwendolyn C/O CABALETTA BIO, INC. 2929 ARCH STREET, SUITE 600 PHILADELPHIA PA 19104 false true false false See Remarks false Common Stock 2024-01-19 4 M false 11000 1.01 A 31000 D Common Stock 2024-01-19 4 S false 10300 19.5350 D 20700 D Common Stock 2024-01-19 4 S false 700 20.3266 D 20000 D Stock Option (Right to Buy) 1.01 2024-01-19 4 M false 11000 0.00 D 2028-10-28 Common Stock 11000 100756 D These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.16 - $20.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.24 - $20.35. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This option vests over four years, with 25% vested on October 11, 2019, and the remaining shares vesting in 12 equal quarterly installments thereafter. President, Science & Technology By: /s/ Michael Gerard, as Attorney-in-Fact 2024-01-19